Cite
HARVARD Citation
Cheng, Y. et al. (2022). An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase. Journal of clinical pharmacy and therapeutics. pp. 1186-1193. [Online].